References
- IMS Institute for Healthcare InformaticsMedicine use and spending shifts: a review of the use of medicines in the United States in 2014Parsippany, NJIMS Institute for Healthcare Informatics2015
- ManzoliLDe VitoCMarzuilloCBocciaAVillariPOral contraceptives and venous thromboembolismDrug Saf201235319120522283630
- The Food and Drug AdministrationYaz: Warning LetterSilver Spring, MDThe Food and Drug Administration2008 Available from: http://bit.ly/2FjVSbPAccessed March 08, 2018
- GeampanaAPregnancy is more dangerous than the pill: a critical analysis of professional responses to the Yaz/Yasmin controversySocial Sci Med2016166916
- WuCQGrandiSMFilionKBAbenhaimHAJosephLEisenbergMJDrospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic reviewBJOG2013120780181123530659
- de BastosMStegemanBHRosendaalFRCombined oral contraceptives: venous thrombosisCochrane Database Syst Rev20143CD010813
- JickSSDrospirenone-containing oral contraceptives may increase the risk of venous thromboembolismEvid Based Nurs20141737124170817
- DingerJCHeinemannLAJKuhl-HabichDThe safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observationContraception200775534435417434015
- JickHJickSSMyersMWVasilakisCGurewichVRisk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsLancet200534615891593
- NorenGNHopstadiusJBateAShrinkage observed-to-expected ratios for robust and transparent large-scale pattern discoveryStat Methods Med Res2013221576921705438
- SzarfmanAMachadoSGO’NeillRTUse of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports databaseDrug Saf200225638139212071774
- HopstadiusJNorénGNBateAEdwardsIRImpact of stratification on adverse drug reaction surveillanceDrug Saf200831111035104818840023
- LesterJNeyarapallyGALipowskiEGrahamCFHallMDal PanGEvaluation of FDA safety – related drug label changes in 2010Pharmacoepidemiol Drug Saf201322330230523280652
- MooreTJSinghSFurbergCDThe FDA and new safety warningsArch Int Med20121721788022232155
- HennessySStromBLImproving postapproval drug safety surveillance: getting better information soonerAnn Rev Pharmacol Toxicol201555758725292435
- HazellLShakirSAUnder-reporting of adverse drug reactions: a systematic reviewDrug Saf20062938539616689555
- HoffmanKBDemakasARDimbilMTatonettiNPErdmanCBStimulated reporting: the impact of US Food and Drug Administration-issued alerts on the Adverse Event Reporting System (FAERS)Drug Saf2014371197198025255848
- van HunselFvan PuijenbroekEde Jong-van den BergLvan GrootheestKMedia attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statinsPharmacoepidemiol Drug Saf2010191263219953500
- MooreTJCohenMRFurbergCDSerious adverse drug events reported to the Food and Drug Administration, 1998–2005Arch Int Med2007167161752175917846394